Cediranib (CAS 288383-20-0)
CAS Number:
288383-20-0
Molecular Weight:
450.51
Molecular Formula:
C25H27FN4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cediranib is a small molecule inhibitor that operates by inhibiting the activity of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. The synthesis of Cediranib involves a three-step process, commencing with the reaction between a phenylamine and an amide to form a Schiff base. The subsequent step involves the reaction between the Schiff base and a carboxylic acid, leading to the desired product. The final stage entails product purification through recrystallization.
Cediranib (CAS 288383-20-0) References
- Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. | Dietrich, J., et al. 2009. Expert Opin Investig Drugs. 18: 1549-57. PMID: 19671039
- Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. | Abdel-Rahman, O. and Fouad, M. 2014. Crit Rev Oncol Hematol. 92: 194-207. PMID: 25028151
- Cediranib in ovarian cancer: state of the art and future perspectives. | Ruscito, I., et al. 2016. Tumour Biol. 37: 2833-9. PMID: 26753963
- Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. | Ivy, SP., et al. 2016. Expert Opin Investig Drugs. 25: 597-611. PMID: 26899229
- Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. | Tang, W., et al. 2017. Clin Pharmacokinet. 56: 689-702. PMID: 27943222
- The role of Cediranib in ovarian cancer. | Orbegoso, C., et al. 2017. Expert Opin Pharmacother. 18: 1637-1648. PMID: 28933580
- Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. | Paoluzzi, L. and Maki, RG. 2019. JAMA Oncol. 5: 254-260. PMID: 30347044
- Mechanism of Cediranib-Olaparib Combo Revealed. | . 2019. Cancer Discov. 9: 990-991. PMID: 31182430
- Cediranib Maleate-From Crystal Structure Toward Materials Control. | Black, SN., et al. 2020. J Pharm Sci. 109: 1509-1518. PMID: 31884015
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. | Wu, W., et al. 2021. Pharmacol Res. 171: 105780. PMID: 34302977
- Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. | Momeny, M., et al. 2021. Life Sci. 287: 120100. PMID: 34715143
- Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer. | Gopinathan, G., et al. 2022. Mol Cancer Ther. 21: 1030-1043. PMID: 35313341
- Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. | Lee, JM., et al. 2022. Clin Cancer Res. 28: 4186-4193. PMID: 35917514
Inhibitor of:
ALK-1, Angptl1, C1sb, ETL, Flk-1, Flt-1, LOC100040130, neuropilin, Olr1128, Olr532, OTUD6A, PDGFR-beta, PRPF4, VHR, and VSIG10.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cediranib, 5 mg | sc-483599 | 5 mg | $137.00 | |||
Cediranib, 10 mg | sc-483599A | 10 mg | $220.00 | |||
Cediranib, 25 mg | sc-483599B | 25 mg | $406.00 |